Drug Trial Radar · NCT06395883
Dynamics in Bone Turnover Markers During and After Short-term Glucocorticoid Treatment in Patients With an Inflammatory Joint Disease
Last checked: Nov 20, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Jan 1, 2025
Primary completion
Oct 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Diakonhjemmet HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Vestre Viken Hospital Trust; Hormone Laboratory, Aker University Hospital, Oslo, Norway
- First posted
- May 2, 2024
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 25 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Bone turnover markers (BTMs) are recommended as an important tool in follow-up of osteoporosis treatment. However, there is a lack of knowledge in the reliability of BTMs during and after glucocorticoid treatment. Glucocorticoids suppresses BTMs during treatment with at least 30% and, moreover, glucocorticoids increase the risk of fractures. Patients with an inflammatory joint disease are at increased risk of osteoporosis, and disease flares are often treated with glucocorticoids, which in turn can lead to loss in reliability of the BTMs in patients who also are on osteoporosis treatment. There is a need of more knowledge on BTM changes during and after glucocorticoid treatment for optimized patientcare, reduced risk of side effects and reduced health economic costs.
Conditions
- Osteoporosis
- Osteoporosis, Steroid Induced
- Inflammatory Rheumatism
Interventions
Glucocorticoid EffectDrug
Patients with or without glucocorticoid treatment will be observed regarding the level of bone turnover markers (P1NP and CTX1) every 4 weeks til 6 months after the last glucocorticoid dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- P1NP level 3 months after glucocorticoid terminationTime frame: september 2024 til december 2025
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Vestre Viken HF, Drammen
Drammen, Norway · Recruiting
Diakonhjemmet hospital
Oslo, Norway · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.